Skip to main content
SpringerLink
Log in

Complexation of a Poly-l-Arginine with Low Molecular Weight Heparin Enhances Pulmonary Absorption of the Drug

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Purpose

This study tests the hypothesis that complexation between a cationic polymer, poly-l-arginine (PLA), and an anionic drug, low molecular weight heparin (LMWH), enhances pulmonary absorption and reduces the epithelial toxicity.

Materials and Methods

Enoxaparin, a LMWH, was complexed with PLAs of different molecular weights at varying concentrations. The resulting complexes were characterized by measuring particle size and zeta potential, and by quantitating the interactions between PLA and enoxaparin using an azure A assay. Changes in transepithelial electrical resistance (TEER) and cytotoxicity induced by enoxaparin–PLA complex were investigated in Calu-3 cells. Pulmonary absorption of LMWH was determined by measuring plasma anti-factor Xa levels. A bronchoalveolar lavage (BAL) study was performed to investigate if the PLA-based formulations caused any cellular or biochemical changes in the lungs.

Results

The particle size of enoxaparin–PLA complexes decreased and the zeta potential values of the complex became less negative as the concentration of positively charged PLA in the complex increased. In vitro experiments suggest that addition of enoxaparin–PLA complex to the apical side of a polarized cell monolayer results in a significant increase in permeability to 14C-mannitol and a decrease in TEER. Pulmonary formulations of enoxaparin plus 0.0125% or 0.0625% PLA of molecular weight 93 kDa led to a twofold increase in the relative bioavailability of LMWH compared to the control (enoxaparin plus normal saline). The BAL study showed that the enoxaparin–PLA complex formulation did not elicit any significant increases in marker enzyme activities compared to the normal saline-treated or untreated control groups.

Conclusion

PLA could be used as a carrier for the pulmonary delivery of LMWH.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. H. Natsume, S. Iwata, K. Ohtake, M. Miyamato, M. Yamaguchi, K. Hosoya, D. Kobayashi, K. Sugibayashi, and Y. Morimoto. Screening of cationic compounds as an absorption enhancer for nasal drug delivery. Int. J. Pharm. 185:1–12 (1999).

    Article  PubMed  CAS  Google Scholar 

  2. M. Miyamoto, H. Natsume, S. Iwata, K. Ohtake, M. Yamaguchi, D. Kobayashi, K. Sugibayashi, M. Yamashina, and Y. Morimoto. Improved nasal absorption of drugs using poly-l-arginine: effects of concentration and molecular weight of poly-l-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats. Eur. J. Pharm. Biopharm. 52:21–30 (2001).

    Article  PubMed  CAS  Google Scholar 

  3. N. M. Zaki, G. A. S. Awad, N. D. Mortada, and S. S. Abd ElHady. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part I. Influence of formulation variables on drug absorption in anesthetized rats. Int. J. Pharm. 327:89–96 (2006).

    Article  PubMed  CAS  Google Scholar 

  4. M. Miyamoto, H. Natsume, I. Satoh, K. Ohtake, M. Yamaguchi, D. Kobayashi, K. Sugibayashi, and Y. Morimoto. Effect of poly-l-arginine on the nasal absorption of FITC-dextran of different molecular weights and recombinant human granulocyte colony-stimulating factor (rhG-CSF) in rats. Int. J. Pharm. 226:127–138 (2001).

    Article  PubMed  CAS  Google Scholar 

  5. N. M. Zaki, N. D. Mortada, G. A. S. Awad, and S. S. Abd ElHady. Rapid-onset intranasal delivery of metoclopramide hydrochloride Part II: Safety of various absorption enhancers and pharmacokinetic evaluation. Int. J. Pharm. 327:97–103(2006).

    Article  PubMed  CAS  Google Scholar 

  6. S. Deshayes, M. C. Morris, G. Divita, and F. Heitz. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol. Life Sci. 62:1839–1849 (2005).

    Article  PubMed  CAS  Google Scholar 

  7. H. Matsui, K. Tomizawa, Y. F. Lu, and M. Matsushita. Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr. Protein Pept. Sci. 4:151–157 (2003).

    Article  PubMed  CAS  Google Scholar 

  8. K. Ohtake, T. Maeno, H. Ueda, H. Natsume, and Y. Morimoto. Poly-l-arginine predominantly increases the paracellular permeability of hydrophilic macromolecules across rabbit nasal epithelium in vitro. Pharm. Res. 20:153–160 (2003).

    Article  PubMed  CAS  Google Scholar 

  9. Y. Huang and M. D. Donovan. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv. Drug Deliv. Rev. 29:147–155 (1998).

    Article  Google Scholar 

  10. K. Yamada, M. Odomi, N. Okada, T. Fujita, and A. Yamamoto. Chitosan oligomers as potential and safe absorption enhancers for improving the pulmonary absorption of interferon-alpha in rats. J. Pharm. Sci. 94:2432–2440 (2005).

    Article  PubMed  CAS  Google Scholar 

  11. B. I. Florea, M. Thanou, H. E. Junginger, and G. Borchard. Enhancement of bronchial octreotide absorption by chitosan and N-trimethyl chitosan shows linear in vitro/in vivo correlation. J. Control. Release 110:353–361 (2006).

    Article  PubMed  CAS  Google Scholar 

  12. R. U. Agu, M. I. Ugwoke, M. Armand, R. Kinget, and N. Verbeke. The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir. Res. 2:198–209 (2001).

    Article  PubMed  CAS  Google Scholar 

  13. J. Yu and Y. W. Chien. Pulmonary drug delivery: physiologic and mechanistic aspects. Crit. Rev. Ther. Drug Carrier Syst. 14:395–453 (1997).

    PubMed  CAS  Google Scholar 

  14. F. Komada, S. Iwakawa, N. Yamamoto, H. Sakakibara, and K. Okumura. Intratracheal delivery of peptide and protein agents: absorption from solution and dry powder by rat lung. J. Pharm. Sci. 83:863–867 (1994).

    Article  PubMed  CAS  Google Scholar 

  15. D. C. Souza-Costa, T. Zerbini, I. F. Metzger, J. B. Rocha, R. F. Gerlach, and J. E. Tanus-Santos. l-Arginine attenuates acute pulmonary embolism-induced oxidative stress and pulmonary hypertension. Nitric Oxide 12:9–14 (2005).

    Article  PubMed  CAS  Google Scholar 

  16. S. J. Chu, T. Y. Lee, H. C. Yan, S. H. Lin, and M. H. Li. l-Arginine prevents air embolism-induced acute lung injury in rats. Crit. Care Med. 33:2056–2060 (2005).

    Article  PubMed  CAS  Google Scholar 

  17. R. D. Hull, G. E. Raskob, R. F. Brant, G. F. Pineo, G. Elliott, P. D. Stein, A. Gottschalk, K. A. Valentine, and A. F. Mah. Low molecular weight heparin vs heparin in the treatment of patients with pulmonary embolism. Arch. Intern. Med. 160:229–236 (2000).

    Article  PubMed  CAS  Google Scholar 

  18. S. Kaul and P. K. Shah. Low molecular weight heparin in acute coronary syndrome: Evidence for superior or equivalent efficacy compared with unfractionated heparin? J. Amer. Coll. Card. 35:1699–1712 (2000).

    Article  CAS  Google Scholar 

  19. R. I. Shulman. Assessment of low-molecular-weight heparin trials in cardiology. Pharmaco. Ther. 87:1–9 (2000).

    Article  CAS  Google Scholar 

  20. K. Salartash, M. D. Gonze, A. Leone-Bay, R. Baughman, C. Sternbergh III, and S. R. Money. Oral low-molecular weight heparin and delivery agent prevents jugular venous thrombosis in the rat. J. Vasc. Surg. 30:526–532 (1999).

    Article  PubMed  CAS  Google Scholar 

  21. J. J. Arnold, F. Ahsan, E. Meezan, and D. J. Pillion. Nasal administration of low molecular weight heparin. J. Pharm. Sci. 91:1707–1714 (2002).

    Article  CAS  Google Scholar 

  22. T. Yang, F. Mustafa, and F. Ahsan. Alkanoylsucroses in nasal delivery of low molecular weight heparins: in-vivo absorption and reversibility studies in rats. J. Pharm. Pharmacol. 56:53–60 (2004).

    Article  PubMed  CAS  Google Scholar 

  23. M. Cadene, C. Boudier, G. D. de Marcillac, and J. G. Bieth. Influence of low molecular mass heparin on the kinetics of neutrophil elastase inhibition by mucus proteinase inhibitor. J. Biol. Chem. 270:13204–13209 (1995).

    Article  PubMed  CAS  Google Scholar 

  24. D. A. Scudiero, R. H. Shoemaker, K. D. Paull, A. Monks, S. Tierney, T. H. Nofziger, M. J. Currens, D. Seniff, and M. R. Boyd. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 48:4827–4833 (1988).

    PubMed  CAS  Google Scholar 

  25. T. Yang, F. Mustafa, S. Bai, and F. Ahsan. Pulmonary delivery of low molecular weight heparins. Pharm. Res. 21:2009–2016 (2004).

    Article  PubMed  CAS  Google Scholar 

  26. A. Hussain and F. Ahsan. State of insulin self-association does not affect its absorption from the pulmonary route. Eur. J. Pharm. Sci. 25:289–298 (2005).

    PubMed  CAS  Google Scholar 

  27. P. R. Dash, M. L. Read, L. B. Barrett, M. A. Wolfert, and L. W. Seymour. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery. Gene Ther. 6:643–650 (1999).

    Article  PubMed  CAS  Google Scholar 

  28. H-M. Buchhammer, M. Mende, and M. Oelmann. Formation of mono-sized polyelectrolyte complex dispersions: effects of polymer structure, concentration and mixing conditions. Colloids and Surfaces A: Physicochem. Eng. Aspects 218:151–159 (2003).

    Article  CAS  Google Scholar 

  29. K. Tadano-Aritomi and I. Ishizuka. Determination of peracetylated sulfoglycolipids using the azure A method. J. Lipid Res. 24:1368–1375 (1983).

    PubMed  CAS  Google Scholar 

  30. S. R. Gundry, M. D. Klein, R. A. Drongowski, and M. M. Kirsh. Clinical evaluation of a new rapid heparin assay using the dye azure A. Am. J. Surg. 148:191–194 (1984).

    Article  PubMed  CAS  Google Scholar 

  31. T. Yang, A. Hussain, S. Bai, I.A. Khalil, H. Harashima, and F. Ahsan. Positively charged polyethylenimines enhance nasal absorption of the negatively charged drug, low molecular weight heparin. J. Control. Release 115:289–297 (2006).

    Article  PubMed  CAS  Google Scholar 

  32. K. A. Foster, M. L. Avery, M. Yazdanian, and K. L. Audus. Characterization of the Calu-3 cell line as a tool to screen pulmonary drug delivery. Int. J. Pharm. 208:1–11 (2000).

    Article  PubMed  CAS  Google Scholar 

  33. N. R. Mathia, J. Timoszyk, P. I. Stetsko, J. R. Megill, R. L. Smith, and D. A. Wall. Permeability characteristics of calu-3 human bronchial epithelial cells: in vitro–in vivo correlation to predict lung absorption in rats. J. Drug Target. 10:31–40 (2002).

    Article  PubMed  Google Scholar 

  34. B. Forbes. Human airway epithelial cell lines for in vitro drug transport and metabolism studies. Pharm. Sci. Tech. Today 3:18–27 (2000).

    Article  CAS  Google Scholar 

  35. G. Wang, J. Zabner, C. Deering, J. Launspach, J. Shao, M. Bodner, D. J. Jolly, B. L. Davidson, and P. B. McCray. Increasing epithelial junction permeability enhances gene transfer to airway epithelia in vivo. Am. J. Respir. Cell Mol. Biol. 22:129–138 (2000).

    PubMed  Google Scholar 

  36. P. Bianchini, G. L. Bergonzini, B. Parma, and B. N. Osima. Relationship between plasma anti-factor Xa activity and the antithrombotic activity of heparins of different molecular mass. Homeostasis 25:288–298 (1995).

    CAS  Google Scholar 

  37. D. C. Litzinger, A. M. Buiting, N. van Rooijen, and L. Huang. Effect of liposome size on the circulation time and intraorgan distribution of amphipathic poly(ethylene glycol)-containing liposomes. Biochim. Biophys. Acta 1190:99–107 (1994).

    Article  PubMed  CAS  Google Scholar 

  38. D. A. Uchida, C. G. Irvin, C. Ballowe, G. Larsen, and G. R. Cott. Cationic proteins increase the permeability of cultured rabbit tracheal epithelial cells: modification by heparin and extracellular calcium. Exp. Lung Res. 22:85–99 (1996).

    Article  PubMed  CAS  Google Scholar 

  39. M. Hammes and A. Singh. Effect of polycations on permeability of glomerular epithelial cell monolayers to albumin. J. Lab. Clin. Med. 123:437–446 (1994).

    PubMed  CAS  Google Scholar 

  40. L. Illum, N. F. Farraj, and S. S. Davis. Chitosan as a novel delivery system for peptide drugs. Pharm. Res. 11:1186–1189 (1994).

    Article  PubMed  CAS  Google Scholar 

  41. G. T. McEwan, M. A. Jepson, B. H. Hirst, and N. L. Simmons. Polycation-induced enhancement of epithelial paracellular permeability is independent of tight junctional characteristics. Biochim. Biophys. Acta 1148:51–60 (1993).

    Article  PubMed  CAS  Google Scholar 

  42. N. G. Schipper, S. Olsson, J. A. Hoogstraate, A. G. deBoer, K. M. Varum, and P. Artursson. Chitosan as absorption enhancers for poorly absorbable drugs 2: mechanism of absorption enhancement. Pharm. Res. 14:923–929 (1997).

    Article  PubMed  CAS  Google Scholar 

  43. J. Wang, S. Sakai, Y. Deguchi, D. Bi, Y. Tabata, and K. Morimoto. Aminated gelatin as a nasal absorption enhancer for peptide drugs: evaluation of absorption enhancing effect and nasal mucosa perturbation in rats. J. Pharm. Pharmacol. 54:181–188 (2002).

    Article  PubMed  CAS  Google Scholar 

  44. A. C. Hunter. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. Adv. Drug Deliv. Rev. 58:1523–1531 (2006).

    Article  PubMed  CAS  Google Scholar 

  45. S. Shahana, C. Kampf, and G. M. Roomans. Effect of the cationic protein poly-l-arginine on airway epithelial cells in vitro. Mediators Inflamm. 11:141–148 (2002).

    Article  PubMed  CAS  Google Scholar 

  46. D. Fischer, T. Bieber, Y. Li, H. P. Elsasser, and T. Kissel. A novel non-viral vector for DNA delivery based on low molecular weight, branched polyethylenimine: effect of molecular weight on transfection efficiency and cytotoxicity. Pharm. Res. 16:1273–1279 (1999).

    Article  PubMed  CAS  Google Scholar 

  47. R. F. Henderson, J. M. Benson, F. F. Hahn, C. H. Hobbs, R. K. Jones, J. L. Muaderly, R. O. McClellan, and J. A. Pickrell. New approaches for the evaluation of pulmonary toxicity: bronchoalveolar lavage fluid analysis. Fund. Appl. Toxicol. 5:451–458 (1985).

    Article  CAS  Google Scholar 

  48. D. B. DeNicola, A. H. Rebar, and R. F. Henderson. Early damage indications in the lung. V. Biochemical and cytological response to NO2 inhalation. Toxicol. Appl. Pharmacol. 60:301–312 (1981).

    Article  PubMed  CAS  Google Scholar 

  49. A. J. Hickey and L. Garcia-Contreras. Immunological and toxicological implication of short-term studies in animals of pharmaceutical aerosol delivery to the lungs: relevance to humans. Crit. Rev. Ther. Drug Carrier Syst. 18:387–431 (2001).

    PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported in part by an NIH grant R15 HL7713301 (FA).

Author information

Author notes

  1. Alamdar Hussain

    Present address: Department of Basic Pharmaceutical Sciences, College of Pharmacy, University of Louisiana, 700 University Blvd, Monroe, Louisiana, 71209, USA

Authors and Affiliations

  1. Department of Pharmaceutical Sciences, School of Pharmacy, Health Sciences Center, Texas Tech University, 1300 Coulter Drive, Amarillo, Texas, 79106, USA

    Amit Rawat, Tianzhi Yang, Alamdar Hussain & Fakhrul Ahsan

Authors
  1. Amit Rawat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tianzhi Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Alamdar Hussain
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Fakhrul Ahsan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fakhrul Ahsan.

Additional information

Amit Rawat and Tianzhi Yang had an equal contribution to the manuscript.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rawat, A., Yang, T., Hussain, A. et al. Complexation of a Poly-l-Arginine with Low Molecular Weight Heparin Enhances Pulmonary Absorption of the Drug. Pharm Res 25, 936–948 (2008). https://doi.org/10.1007/s11095-007-9442-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-007-9442-x

Key words

Search

Navigation